Thromb Haemost 1985; 54(02): 539-543
DOI: 10.1055/s-0038-1657892
Original Article
Schattauer GmbH Stuttgart

Plasma Concentrations of Platelet-Specific Proteins in Different Stages of Essential Hypertension: Interactions between Platelet Aggregation, Blood Lipids and Age

J Yamanishi
The First Department of Internal Medicine, Kobe University School of Medicine, Kobe, Japan
,
H Sano
The First Department of Internal Medicine, Kobe University School of Medicine, Kobe, Japan
,
K Saito
The First Department of Internal Medicine, Kobe University School of Medicine, Kobe, Japan
,
Y Furuta
The First Department of Internal Medicine, Kobe University School of Medicine, Kobe, Japan
,
H Fukuzaki
The First Department of Internal Medicine, Kobe University School of Medicine, Kobe, Japan
› Author Affiliations
Further Information

Publication History

Received 19 March 1985

Accepted 25 June 1985

Publication Date:
18 July 2018 (online)

Summary

Plasma β-thromboglobulin (βTG) and platelet factor 4 (PF4) were significantly higher in a group of 116 hypertensive men than in a normotensive group of 142 men. They increased with the stage of hypertension but the level did not correlate with the age of the subjects. Platelet aggregation was similar in the two groups and positively correlated with the age of the subjects in the normotensive group but not in the hypertensive group. A strong positive correlation was observed between the levels of plasma βTG and PF4 and between platelet aggregation to ADP and that to epinephrine in both the hypertensive and normotensive groups. However, there was no correlation between the level of plasma βTG or PF4 and platelet aggregation. Plasma antithrombin III was lower in the hypertensive group than in the normotensive group.

These studies suggest that plasma levels of PTG and PF4 are closely related to the stage of hypertension and are better indicators than aggregation of in vivo platelet activation in hypertensive subjects. Enhanced platelet activation may be involved in the acceleration of hypertensive arteriovascular damage and atherosclerosis.

 
  • References

  • 1 Young W, Gofman JW, Tandy R, Malamud N, Waters ESG. The quantitation of atherosclerosis, II. quantitative aspects of the relationship of blood pressure and atherosclerosis. Am J Cardiol 1960; 06: 294-299
  • 2 Baker AB, Resch JA, Loewenson RB. Hypertension and cerebral atherosclerosis. Circulation 1969; 39: 701-710
  • 3 Mustard JF, Murphy EA, Rowsell HC, Downie HG. Platelets and atherosclerosis. J Atheroscler Res 1964; 04: 01-28
  • 4 Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976; 295: 369-377 420
  • 5 Steele PP, Weily HS, Davies H, Genton E. Platelet function studies in coronary artery disease. Circulation 1973; 48: 1194-1200
  • 6 Acheson J, Danta G, Hutchinson EC. Platelet adhesiveness in patients with cerebral vascular disease. Atherosclerosis 1972; 15: 123-127
  • 7 Johnson M, Ramey E, Ramwell PW. Sex and age differences in human platelet aggregation. Nature 1975; 253: 355-357
  • 8 Yokoyama M, Kawashima S, Sakamoto S, Akita H, Okada T, Mizutani T, Fukuzaki H. Platelet reactivity and its dependence on alpha-adrenergic receptor function in patients with ischaemic heart disease. Br Heart J 1983; 49: 20-25
  • 9 Carvalho ACA, Colman RW, Lees RS. Platelet function in hyperlipoproteinemia. N Engl J Med 1974; 290: 434-438
  • 10 Kwaan HC, Colwell JA, Cruz S, Suwanwela N, Dobbie JG. Increased platelet aggregation in diabetes mellitus. J Lab Clin Med 1972; 80: 236-246
  • 11 Poplawski A, Skorulska M, Niewiarowski S. Increased platelet adhesiveness in hypertensive cardiovascular disease. J Atheroscler Res 1968; 08: 721-723
  • 12 Coccheri S, Fiorentini P. Platelet adhesiveness and aggregation in hypertensive patients. Acta Med Scand Suppl 1971; 525: 273-275
  • 13 Vlachakis ND, Aledort FL. Hypertension and propranolol therapy: effect on blood pressure, plasma catecholamines and platelet aggregation. Am J Cardiol 1980; 45: 321-325
  • 14 Kaplan KL. Platelet granule proteins: localization and secretion. In: Platelets in Biology and Pathology 2. Gordon JL. (Ed). Elsevier/North-Holland Biomedical Press; Amsterdam: 05 1981: 77-90
  • 15 Smith RC, Duncanson J, Ruckley CV, Webber RG, Allan NC, Dawes J, Bolton AE, Hunter WM, Pepper DS, Cash JD. β-thromboglobulin and deep vein thrombosis. Thromb Haemostas 1978; 39: 338-345
  • 16 Doyle DJ, Chesterman CN, Cade JF, McGready JR, Rennie GC, Morgan FJ. Plasma concentrations of platelet-specific proteins correlated with platelet survival. Blood 1980; 55: 82-84
  • 17 Cella G, Zahavi J, de Haas HA, Kakkar VV. β-thromboglobulin, platelet production time and platelet function in vascular disease. Br J Haematol 1979; 43: 127-136
  • 18 Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929
  • 19 Ludlam CA, Moore S, Bolton AE, Pepper DS, Cash JD. The release of a human platelet specific protein measured by a radio immunoassay. Thromb Res 1975; 06: 543-548
  • 20 Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20: 470-475
  • 21 Eggstein M, Kreutz FH. Eine neue Bestimmung der Neutralfette in Blutserum und Gewebe. Klin Wochenschr 1966; 44: 262-267
  • 22 Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 1970; 11: 583-595
  • 23 Petralito A, Fiore CE, Mangiafico RA, Malatino LS. Beta-thromboglobulin plasma levels in different stages of arterial hypertension. Thromb Haemostas 1982; 48: 241
  • 24 Mehta J, Mehta P. Platelet function in hypertension and effect of therapy. Am J Cardiol 1981; 47: 331-334
  • 25 Andrassy K, Deppermann D, Ritz E, Koderisch J, Seeling H. Different effects of renal failure on beta-thromboglobulin and high affinity platelet factor 4 (HA-PF4)-concentrations. Thromb Res 1980; 18: 469-475
  • 26 Torsellini A, Becucci A, Citi S, Cozzolino F, Guidi G, Lombaridi V, Vercelli D, Veloci M. Effects of pressure excursions on human platelets. In vitro studies on beta thromboglobulin (βTG) and platelet factor 4 (PF4) release and on platelet sensitivity to ADP-aggregation. Haematologica 1982; 67: 860-866
  • 27 Bowie EJW, Owen Jr CA. Some factors influencing platelet retension in glass bead columns including the influence of plastics. Am J Clin Pathol 1971; 71 (Suppl. 56) 479-483
  • 28 Yokoyama M, Kusui A, Sakamoto S, Fukuzaki H. Age-associated increments in human platelet α-adrenoreceptor capacity: possible mechanism for platelet hyperactivity to epinephrine in aging man. Thromb Res 1984; 34: 287-295
  • 29 Folts JD, Crowell EB, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976; 54: 365-370
  • 30 Zahavi J, Betteridge JD, Jones NAG, Galton DJ, Kakkar VV. Enhanced in vivo platelet release reaction and malondialdehyde formation in patients with hyperlipidemia. Am J Med 1981; 70: 59-64
  • 31 Sadoshima S, Kurozumi T, Tanaka K, Ueda K, Takeshita M, Hirota Y, Omae T, Uzawa H, Katsuki S. Cerebral and aortic atherosclerosis in Hisayama, Japan. Atherosclerosis 1980; 36: 117-126
  • 32 Sano K, Takai Y, Yamanishi J, Nishizuka Y. A role of calcium-activated phospholipid-dependent protein kinase in human platelet activation. J Biol Chem 1983; 258: 2010-2013
  • 33 Bick RL, Kovacs I, Fekete LF. A new two-stage functional assay for antithrombin-III (heparin cofactor): Clinical and laboratory evaluation. Thromb Res 1976; 08: 745-756
  • 34 Bick RL, Dukes ML, Wilson WL, Fekete LF. Antithrombin III (AT-III) as a diagnostic aid in disseminated intravascular coagulation. Thromb Res 1977; 10: 721-729